Imanivec (Imatinib)

Imanivec (imatinib) is a tyrosine kinase inhibitor used in malignancies driven by specific kinase mutations.

• Chronic myeloid leukemia: reduces disease burden and improves survival by targeting BCR‑ABL‑positive cells.
• Philadelphia‑positive acute lymphoblastic leukemia: induces remission by inhibiting BCR‑ABL signaling.
• Gastrointestinal stromal tumor: controls tumor growth by blocking c‑KIT and PDGFR activity.

• Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This blocks downstream phosphorylation cascades that drive uncontrolled cell proliferation, thereby inducing apoptosis or growth arrest in malignant cells that depend on these kinases for survival.

Imanivec may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Edema: swelling of the hands, feet, or face.
• Fatigue: persistent tiredness.
• Muscle cramps: painful tightening of muscles.
• Diarrhoea: loose stools.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Neutropenia: dangerously low white‑blood‑cell count.
• Thrombocytopenia: reduced platelet levels leading to bleeding risk.
• Hepatotoxicity: liver enzyme elevation or injury.
• Cardiac failure: signs of reduced heart function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: elevated pressure in lung arteries.

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: check hepatic enzymes periodically.
• Evaluate cardiac status: consider ECG or echocardiogram in patients with heart disease.
• Review concomitant medications: avoid drugs that strongly affect CYP3A4 metabolism.
• Pregnancy and lactation: discuss risks with women of childbearing potential.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Imanivec interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy.
• QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Oral contraceptives: possible reduced hormonal efficacy.
• H2‑blockers or antacids: may affect absorption, separate dosing times.
• CYP2C8 inhibitors (e.g., gemfibrozil): modest increase in exposure.
• Proton‑pump inhibitors: monitor for altered gastric pH affecting drug uptake.